Sofinnova Partners Closes €82 Million Medtech Venture Fund

Sofinnova Partners has closed an €82 million venture capital fund dedicated to medical technology, according to Medical Device Network.

The close confirms fresh, dedicated capital for the medtech asset class at a time when many European health investors remain cautious. An €82 million vehicle is a mid-sized fund by life-science standards. Its arrival signals that limited partners are still willing to commit new money to medical device and diagnostics companies.

Sofinnova Partners is an established European life sciences investor. The firm has historically deployed capital across biopharmaceuticals, medical devices and digital health. A dedicated medtech vehicle concentrates its firepower on hardware, diagnostics and device-adjacent companies rather than spreading commitments across the broader life sciences spectrum.

The fund's size shapes what it can do. At €82 million, the vehicle can lead or co-invest in early-stage rounds, support portfolio companies through follow-on financing, and build a portfolio spread across a number of medical technology bets. It is not sized for late-stage mega-rounds, which points the fund toward seed and Series A companies where capital efficiency matters most.

For founders, the close matters concretely. A new fund means a new source of term-sheet-ready capital in European medtech, a sector where specialized investors are scarcer than in biopharma. Medical device companies face long regulatory pathways and capital-intensive clinical work, so the pool of investors willing to underwrite that timeline is limited.

The close also lands amid a broader reset in venture fundraising. Health-focused funds across Europe and the United States have taken longer to raise in the past two years as limited partners pulled back from the record deployment years of 2021 and early 2022. Against that backdrop, reaching a final close of €82 million represents a completed commitment cycle rather than an interim announcement.

Medical Device Network reported the final close. The outlet did not disclose the fund's limited partners, its investment period, or specific target sectors within medical technology in the initial report.

What comes next is deployment. The measure of the fund will be its first announced investments — which device categories Sofinnova Partners backs, at what stage, and on what terms — and those deals will define whether the €82 million translates into a durable medtech portfolio.